Targeting PAPPA2, either via T cell engineering43or direct binding of anticancer drugs, potentially in combination with checkpoint inhibition therapy, could present as the optimal therapeutic approach for patients who recur after localized disease management or present with upfront metastatic disease. Here, PAPPA2 is linked to metastatic neoplasm.